MX2022004806A - Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763). - Google Patents
Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763).Info
- Publication number
- MX2022004806A MX2022004806A MX2022004806A MX2022004806A MX2022004806A MX 2022004806 A MX2022004806 A MX 2022004806A MX 2022004806 A MX2022004806 A MX 2022004806A MX 2022004806 A MX2022004806 A MX 2022004806A MX 2022004806 A MX2022004806 A MX 2022004806A
- Authority
- MX
- Mexico
- Prior art keywords
- vit
- nice
- anemia
- compositions
- methods
- Prior art date
Links
- 108091006976 SLC40A1 Proteins 0.000 title 1
- 208000007502 anemia Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- KNYVRFXIVWUGBZ-UHFFFAOYSA-N vamifeport Chemical compound N1C(=NC2=C1C=CC=C2)CCNCCC=1OC=C(N=1)C(=O)NCC1=NC=CC=C1F KNYVRFXIVWUGBZ-UHFFFAOYSA-N 0.000 title 1
- 208000035868 Vascular inflammations Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924556P | 2019-10-22 | 2019-10-22 | |
| EP19000483 | 2019-10-22 | ||
| EP20163777 | 2020-03-17 | ||
| EP20176336 | 2020-05-25 | ||
| PCT/EP2020/079802 WO2021078889A1 (en) | 2019-10-22 | 2020-10-22 | Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004806A true MX2022004806A (es) | 2022-05-16 |
Family
ID=73005635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004806A MX2022004806A (es) | 2019-10-22 | 2020-10-22 | Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220274973A1 (https=) |
| EP (1) | EP4048262A1 (https=) |
| JP (1) | JP7594004B2 (https=) |
| KR (1) | KR20220086563A (https=) |
| CN (1) | CN114765955B (https=) |
| AU (1) | AU2020369137A1 (https=) |
| BR (1) | BR112022007616A2 (https=) |
| CA (1) | CA3154524A1 (https=) |
| IL (1) | IL291137A (https=) |
| MX (1) | MX2022004806A (https=) |
| WO (1) | WO2021078889A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025535398A (ja) | 2022-10-21 | 2025-10-24 | ビフォー （インターナショナル） エージー | 二環式フェロポーチン阻害剤 |
| EP4731218A1 (en) | 2023-06-26 | 2026-04-29 | Vifor (International) AG | Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh) |
| WO2026041650A1 (en) | 2024-08-20 | 2026-02-26 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of lupus nephritis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002416C (en) | 2015-10-23 | 2023-10-24 | Vifor (International) Ag | Benzimidazolyl derivatives for use as ferroportin inhibitors |
| US11191818B2 (en) * | 2016-08-04 | 2021-12-07 | Takeda Pharmaceutical Company Limited | Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome |
| JOP20180036A1 (ar) * | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| ES2934492T3 (es) | 2018-12-13 | 2023-02-22 | Global Blood Therapeutics Inc | Inhibidores de ferroportina y métodos de uso |
-
2020
- 2020-10-22 AU AU2020369137A patent/AU2020369137A1/en active Pending
- 2020-10-22 JP JP2022523485A patent/JP7594004B2/ja active Active
- 2020-10-22 EP EP20796575.7A patent/EP4048262A1/en active Pending
- 2020-10-22 MX MX2022004806A patent/MX2022004806A/es unknown
- 2020-10-22 BR BR112022007616A patent/BR112022007616A2/pt unknown
- 2020-10-22 US US17/636,575 patent/US20220274973A1/en not_active Abandoned
- 2020-10-22 CA CA3154524A patent/CA3154524A1/en active Pending
- 2020-10-22 CN CN202080074094.0A patent/CN114765955B/zh active Active
- 2020-10-22 WO PCT/EP2020/079802 patent/WO2021078889A1/en not_active Ceased
- 2020-10-22 KR KR1020227012237A patent/KR20220086563A/ko active Pending
-
2022
- 2022-03-06 IL IL291137A patent/IL291137A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023500060A (ja) | 2023-01-04 |
| CA3154524A1 (en) | 2021-04-21 |
| IL291137A (en) | 2022-05-01 |
| US20220274973A1 (en) | 2022-09-01 |
| JP7594004B2 (ja) | 2024-12-03 |
| WO2021078889A1 (en) | 2021-04-29 |
| KR20220086563A (ko) | 2022-06-23 |
| AU2020369137A1 (en) | 2022-04-07 |
| CN114765955B (zh) | 2025-06-24 |
| EP4048262A1 (en) | 2022-08-31 |
| BR112022007616A2 (pt) | 2022-07-12 |
| CN114765955A (zh) | 2022-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| PH12022550469A1 (en) | Kras g12d inhibitors | |
| MX2022000711A (es) | Inhibidores de parp1. | |
| MX2024008551A (es) | Terapias de combinacion. | |
| EA202090419A1 (ru) | Селективные ингибиторы инфламмасомы nlrp3 | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| MX394961B (es) | Composiciones para usarse en el tratamiento de enfermedades relacionadas con la interleucina 6 | |
| JOP20190229A1 (ar) | مركبات تثبط بروتين mcl-1 | |
| EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| NZ708593A (en) | Novel pyrazole derivative | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| MX384721B (es) | Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201791576A1 (ru) | Ингибитор jak | |
| EA201790779A1 (ru) | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы |